SCHEMBL5538373

SCHEMBL5538373

Cc1cc(F)ccc1NC(=S)N(C)C1CCCCC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.55
▸ KCNH2 Q12809 1/20 0.54
▸ ABCC1 P33527 4/20 0.53
▸ MAPT P10636 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ GAA P10253 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ LMNA P02545 3/20 0.49
▸ NPC1 O15118 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ RAB9A P51151 1/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5527031 0.83 MAPT (0.56) POLBABCC1MAPTALDH1A1GAA
SCHEMBL5530519 0.80 POLB (0.58) POLBABCC1MAPTALDH1A1GAA
SCHEMBL27782882 0.77 ABCC1 (0.57) POLBKCNH2ABCC1MAPTALDH1A1
SCHEMBL5526949 0.73 ABCC1 (0.63) POLBABCC1MAPTALDH1A1GAA
SCHEMBL5530231 0.73 POLB (0.58) POLBABCC1MAPTALDH1A1GAA
SCHEMBL5531640 0.73 ABCC1 (0.59) POLBKCNH2ABCC1MAPTALDH1A1
SCHEMBL5529178 0.73 POLB (0.55) POLBABCC1MAPTALDH1A1GAA
SCHEMBL5532573 0.71 ABCC1 (0.51) POLBKCNH2ABCC1MAPTALDH1A1
SCHEMBL27264919 0.71 HTT (0.64) POLBKCNH2ABCC1GAANPC1
SCHEMBL5463743 0.71 MAPT (0.77) POLBKCNH2ABCC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 POLB 4518/4885KCNH2 2178/4885ABCC1 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback